top of page

iQure Pharma Selected to Join NYU Stern Endless Frontier Labs (EFL) 2022-2023 Life Sciences Track

Updated: Sep 19, 2022

iQure Pharma is one of 25 companies invited to join the NYU Stern School of Business Endless Frontier Labs 2022-2023 cohort dedicated to companies developing treatments that address unmet health needs focused on Life Sciences.

Princeton, NJ, September 19, 2022 ─ iQure Pharma Inc. (iQure), a Princeton-based global biotech company focused on developing novel treatments for neuropathic pain, has announced that it has been selected out of over 1100 companies into the high-profile accelerator EFL, run by the renowned Stern School of Business Business at New York University.

“We are excited to announce that iQure has been selected to join the Endless Frontier Labs 2022-2023 cohort!” said Pawel Zolnierczyk, iQure CEO. “We look forward to working alongside EFL mentors, NYU Stern MBA students, and the other great companies selected for the Life Sciences track.”

Endless Frontier Labs (EFL), a program for early-stage science and technology-based start-ups at New York University’s Stern School of Business, is structured to optimize each start-up’s chance of scaling into a successful company through a goals-based mentoring process. EFL mentors are experienced entrepreneurs who have built and exited successful companies, world-renowned scientists and technical experts, and well-known venture capital and angel investors.

About iQure Pharma

A global biotech firm headquartered in Princeton, New Jersey, iQure Pharma is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies. For more information about supporting iQure’s initiatives, contact iQure CFO Dr. Anna Rzewuska at

27 views0 comments

Recent Posts

See All


bottom of page